Pharmacogenomic (PGx) Testing Service
Description: The project wishes to appoint a suitable laboratory or multiple labs to supply an end-to-end genomic testing service which provides genomic variant data for n=4,854 participants in Northern Ireland (NI) and Ireland. Specifically, the areas where the project will recruit participants from of relevance to this tender includes counties Londonderry, Tyrone in Northern Ireland and counties Donegal and Sligo in Ireland. The iMPROVE project will operate on the basis of a research implementation study which aims to integrate pharmacogenomic testing into a patient-centred medicines optimisation care pathway in GP practices across the project regions. The new integrated care pathway will be led by GP practice pharmacists with a focus on medicines optimisation to improve outcomes, removing inappropriate and ineffective treatments and adverse drug event risk reduction. Medications for (read more...)
Summary: The contracting authority, Ulster University, based in Coleraine, UK, has initiated an open tender process under the Northern Irish devolved regulations to provide a Pharmacogenomic (PGx) Testing Service. This project seeks to appoint suitable laboratories to deliver end-to-end genomic testing services for 4,854 participants across strategic locations in Northern Ireland and Ireland. The tender procedure, currently active, involves the submission of applications by 17th June 2026, with the enquiry period ending on 11th June 2026. The procurement, valued at £600,000, is dedicated to services in the miscellaneous health and medical analysis sector and is aligned with the PEACEPLUS Programme for 2021-2027, underlining its broader regulatory compliance.